跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
呂 佩融
教授
臨床醫學研究所
電子郵件
pjlu2190
mail.ncku.edu
tw
h-index
9273
引文
50
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1990 …
2024
每年研究成果
概覽
指紋
網路
專案
(18)
研究成果
(182)
類似的個人檔案
(6)
監製作品
(8)
指紋
查看啟用 Pei-Jung Lu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine & Life Sciences
Solitary Nucleus
100%
Phosphorylation
96%
Neoplasms
63%
quinoline
59%
Proteins
56%
Glycogen Synthase Kinase 3
54%
Phosphatidylinositol 3-Kinase
53%
phosphatidylinositol 3,4,5-triphosphate
52%
Phosphatidylinositols
50%
Esophageal Squamous Cell Carcinoma
48%
Triple Negative Breast Neoplasms
47%
Peptidylprolyl Isomerase
44%
Growth
42%
Lung Neoplasms
40%
MicroRNAs
37%
Inositol Phosphates
33%
Osteopontin
33%
Nitric Oxide Synthase Type III
31%
Blood Pressure
31%
Mouth Neoplasms
31%
Biomarkers
29%
Cyclin D1
29%
Stomach Neoplasms
29%
Profilins
29%
Gastric Juice
28%
Hypertension
28%
WW Domains
27%
Down-Regulation
27%
Catenins
26%
Venoms
26%
Phospholipases A2
26%
Polyphosphates
26%
Carcinogenesis
25%
HeLa Cells
25%
Prostatic Neoplasms
25%
Enzymes
25%
2-styrylchromone
25%
Phosphatidylinositol 4,5-Diphosphate
25%
Calcium
25%
Cell Line
25%
Adenocarcinoma of Lung
24%
In Vitro Techniques
24%
Survival
24%
Cell Cycle
23%
phosphatidylinositol 3,4-diphosphate
23%
Structure-Activity Relationship
22%
Chemical Compounds
Phosphoinositide
64%
Phosphatidylinositol
58%
Antiproliferative
50%
Protein
49%
50 Percent Growth Inhibition
47%
Inositol
36%
Inositol Phosphate
36%
Quinoline
35%
Polyphosphate
29%
Growth Inhibition
28%
Calcium(0)
25%
Venom
23%
Ins(1,4,5)P3
23%
Structure-Activity Relationship
22%
Cyclic ADP-ribose
18%
Glycogen
16%
Collagen
15%
Cell Death
15%
Serine
15%
Phosphatidylinositol 4-Phosphate
15%
Neurotoxicity
15%
Kd
15%
Neurotoxic
14%
Fragmentation
14%
Quinolines
13%
Peptide
12%
Flow
12%
Lipid
11%
Apoptotic
11%
Ceramide Glucosyltransferase Inhibitor
11%
Disorder
11%
Oxalate
10%
Bioavailability
10%
Amino Acid Sequence
10%
Insulin Derivative
10%
Poly(ADPribose)
10%
Antineoplastic Agent
9%
Complementary DNA
9%
EC 3.5.4.4 (Adenosine Deaminase) Inhibitor
9%
Oxime
9%
Block Like Crystal
9%
Neurogenic
9%
Deferiprone
9%
Modification
9%
Aurora
8%
Signal Transduction
8%
Oncogenic
8%
